MCID: MLG069
MIFTS: 47

Malignant Hypertension

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Malignant Hypertension

MalaCards integrated aliases for Malignant Hypertension:

Name: Malignant Hypertension 12 15 17 71
Hypertension, Malignant 43
Hypertension Malignant 54

Classifications:



External Ids:

Disease Ontology 12 DOID:10824
MeSH 43 D006974
NCIt 49 C3118
SNOMED-CT 67 70272006
UMLS 71 C0020540

Summaries for Malignant Hypertension

Disease Ontology : 12 A hypertension that is characterized by rapid onset of extremely high blood pressure.

MalaCards based summary : Malignant Hypertension, also known as hypertension, malignant, is related to malignant hypertensive renal disease and malignant secondary hypertension. An important gene associated with Malignant Hypertension is REN (Renin), and among its related pathways/superpathways are cGMP-PKG signaling pathway and MicroRNAs in cardiomyocyte hypertrophy. The drugs Nifedipine and Losartan have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 A hypertensive emergency is high blood pressure with potentially life-threatening symptoms and signs... more...

Related Diseases for Malignant Hypertension

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Malignant Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 366)
# Related Disease Score Top Affiliating Genes
1 malignant hypertensive renal disease 33.9 REN EDN1 AGTR1
2 malignant secondary hypertension 32.7 REN AGTR1
3 malignant renovascular hypertension 32.7 REN EDN1 AGTR1
4 hemolytic uremic syndrome, atypical 1 31.2 VWF THBD CFHR2 CFH ADAMTS13
5 nephrosclerosis 30.9 AGTR1 ADAMTS13 ACE
6 thrombotic microangiopathy 30.7 VWF CFH ADAMTS13
7 hypertensive encephalopathy 30.6 REN AGTR1 ADAMTS13 ACE
8 hypertensive retinopathy 30.6 VWF REN AGTR1 ADAMTS13 ACE
9 uremia 30.5 VWF REN ACE
10 purpura 30.4 VWF THBD ADAMTS13 ACE
11 cardiac tamponade 30.3 REN NPPB ACE
12 acute kidney failure 30.2 REN NPPA CFH ADAMTS13
13 malignant essential hypertension 30.2 REN ACE
14 hypertension, diastolic 30.2 REN NPPA ACE
15 microvascular complications of diabetes 3 30.1 REN AGTR1 ACE
16 cardiogenic shock 30.1 NPPB ADM
17 hypertensive nephropathy 30.1 AGTR1 ACE
18 takayasu arteritis 30.0 VWF THBD EDN1
19 fibromuscular dysplasia 30.0 REN AGTR1 AGT ACE
20 atrial standstill 1 29.9 NPPB NPPA ACE
21 thrombotic thrombocytopenic purpura 29.9 VWF THBD CFH ADAMTS13
22 hemolytic anemia 29.9 VWF THBD CFH ADAMTS13
23 anuria 29.9 REN AGTR1 AGT ADAMTS13 ACE
24 urinary tract obstruction 29.9 REN AGTR1 ACE
25 retinal vascular disease 29.8 REN EDN1 ACE
26 nonarteritic anterior ischemic optic neuropathy 29.8 EDN1 AGTR1 AGT ACE
27 catastrophic antiphospholipid syndrome 29.7 CFH ADAMTS13
28 conn's syndrome 29.6 REN NPPA CHGA AGTR1 ACE
29 disseminated intravascular coagulation 29.6 VWF THBD ADAMTS13
30 renal hypertension 29.6 REN NPPB EDN1 AGTR1 AGT ADM
31 renovascular hypertension 29.6 REN NPPB NPPA EDN1 AGTR1 ADM
32 microvascular complications of diabetes 5 29.6 AGTR1 AGT ACE
33 renal dysplasia 29.6 REN AGTR1 AGT ACE
34 pericardial effusion 29.6 REN NPPB NPPA ACE
35 antiphospholipid syndrome 29.6 VWF THBD CFH ADAMTS13
36 vesicoureteral reflux 1 29.6 REN AGTR1 AGT ACE
37 cardiac arrest 29.6 THBD REN NPPB ACE
38 portal hypertension 29.5 VWF EDN1 AGTR1 ADAMTS13 ACE
39 iga glomerulonephritis 29.5 REN CFHR2 CFH AGTR1 ACE
40 pheochromocytoma 29.5 REN NPPA EDN1 CHGA ADM ACE
41 vascular disease 29.3 VWF THBD REN NPPB EDN1 AGT
42 eclampsia 29.3 THBD REN EDN1 AGTR1 AGT ACE
43 polycystic kidney disease 29.3 REN EDN1 AGTR1 AGT ACE
44 renal artery disease 29.2 REN NPPA AGTR1 AGT ACE
45 hemolytic-uremic syndrome 29.2 VWF THBD CFHR2 CFH ADAMTS13
46 deficiency anemia 29.0 NPPA CYP1A1 ADAMTS13 ACE
47 coronary artery anomaly 28.9 NPPB NPPA EDN1 AGTR1 ADM ACE
48 pulmonary edema 28.9 REN NPPB NPPA EDN1 AGTR1 AGT
49 end stage renal failure 28.8 THBD REN NPPB NPPA CFHR2 AGTR1
50 connective tissue disease 28.6 EDN1 CFHR2 ADAMTS13 ACE

Graphical network of the top 20 diseases related to Malignant Hypertension:



Diseases related to Malignant Hypertension

Symptoms & Phenotypes for Malignant Hypertension

MGI Mouse Phenotypes related to Malignant Hypertension:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 ACE ADM AGT AGTR1 CFH CHGA
2 homeostasis/metabolism MP:0005376 10.18 ACE ADAMTS13 ADM AGT AGTR1 CFH
3 hematopoietic system MP:0005397 10.14 ACE ADAMTS13 ADM AGTR1 CFH CYP1A1
4 mortality/aging MP:0010768 10.07 ACE ADAMTS13 ADM AGT AGTR1 CFH
5 immune system MP:0005387 10.06 ACE ADAMTS13 ADM AGT AGTR1 CFH
6 muscle MP:0005369 9.76 ADM AGT CFH CHGA EDN1 NPPA
7 nervous system MP:0003631 9.65 AGT AGTR1 CFH CHGA EDN1 REN
8 renal/urinary system MP:0005367 9.32 ACE ADM AGT AGTR1 CFH CHGA

Drugs & Therapeutics for Malignant Hypertension

Drugs for Malignant Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Losartan Approved Phase 4 114798-26-4 3961
3
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
4
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
5
Atenolol Approved Phase 4 29122-68-7 2249
6
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
9
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
10 Hormones Phase 4
11 Tocolytic Agents Phase 4
12 Anti-Arrhythmia Agents Phase 4
13 Adrenergic beta-Antagonists Phase 4
14 Neurotransmitter Agents Phase 4
15 Adrenergic Antagonists Phase 4
16 Adrenergic beta-1 Receptor Antagonists Phase 4
17 Angiotensin II Type 1 Receptor Blockers Phase 4
18 Giapreza Phase 4
19 diuretics Phase 4
20 Sodium Chloride Symporter Inhibitors Phase 4
21 Autonomic Agents Phase 4
22 Angiotensin Receptor Antagonists Phase 4
23 Adrenergic Agents Phase 4
24 Natriuretic Agents Phase 4
25 Sympatholytics Phase 4
26 Angiotensinogen Phase 4
27 Antihypertensive Agents Phase 4
28 HIV Protease Inhibitors Phase 4
29
protease inhibitors Phase 4
30 Vasodilator Agents Phase 4
31 Calcium, Dietary Phase 4
32 calcium channel blockers Phase 4
33 Angiotensin-Converting Enzyme Inhibitors Phase 4
34
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
35
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
36
Atorvastatin Approved Phase 3 134523-00-5 60823
37 Nigella Phase 3
38 Hypoglycemic Agents Phase 3
39
Diazoxide Approved Phase 2 364-98-7 3019
40
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
41
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
42
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
43
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
44
Choline Approved, Nutraceutical Phase 2 62-49-7 305
45 Hypolipidemic Agents Phase 2
46 Nootropic Agents Phase 2
47 Gastrointestinal Agents Phase 2
48 Lipid Regulating Agents Phase 2
49 Antimetabolites Phase 2
50 Etoposide phosphate Phase 1, Phase 2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
2 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
3 Blood Pressure Reduction by Fixed-dose Compared to Free Dose Combination Therapy of ACE Inhibitor and Calcium Antagonist in Hypertensive Patients Completed NCT02995954 Phase 4 Perindopril/Amlodipine
4 Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients Completed NCT01575652 Phase 4
5 Effect of Nigella Sativa Seed Extract on the Blood Pressure of Elderly With Hypertension Unknown status NCT01393054 Phase 3 Nigella sativa
6 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
7 The Benefit of STent Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR) Completed NCT00150943 Phase 3
8 A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects Completed NCT00696475 Phase 2 Diazoxide choline;Diazoxide choline;Diazoxide choline;Placebo
9 Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer Recruiting NCT04182698 Phase 1, Phase 2 Simultaneous chemoradiotherapy for An Luo
10 Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial Unknown status NCT02672995 Phase 1 bevacizumab
11 Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly : a Randomized Controlled Trial Unknown status NCT01834365
12 Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study. Unknown status NCT02099903
13 Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy. Unknown status NCT01870310
14 Single Incision Laparoscopy Completed NCT00616616
15 Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies and Urgencies Completed NCT02924805
16 Assessment of Renal and Cervical Artery DysplasIA Completed NCT02884141
17 Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population Completed NCT00005240
18 Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma Completed NCT01810744
19 Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine Headache: A Randomized Control Trial Completed NCT03479060
20 A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort Recruiting NCT03755726
21 Serum Androgen Levels as a Marker for the Severity of Preeclampsia Active, not recruiting NCT03744988
22 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Malignant Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Captopril
Diazoxide
Enalapril
Enalapril Maleate
Enalaprilat
Fenoldopam
Fenoldopam Mesylate
Hydralazine
Hydralazine Hydrochloride
Labetalol
Labetalol hydrochloride
Mecamylamine
Mecamylamine hydrochloride
Minoxidil
nebivolol
Phenoxybenzamine
Phenoxybenzamine Hydrochloride
Phentolamine
Phentolamine Mesylate
Sodium Nitroprusside
trimethaphan camsylate

Cochrane evidence based reviews: hypertension, malignant

Genetic Tests for Malignant Hypertension

Anatomical Context for Malignant Hypertension

MalaCards organs/tissues related to Malignant Hypertension:

40
Kidney, Heart, Brain, Eye, Liver, Testes, T Cells

Publications for Malignant Hypertension

Articles related to Malignant Hypertension:

(show top 50) (show all 1954)
# Title Authors PMID Year
1
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. 54 61
18332284 2008
2
The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. 54 61
17679041 2007
3
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. 54 61
17485026 2007
4
Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension. 54 61
15655381 2005
5
The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations. 54 61
14769441 2004
6
Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE inhibitor. 54 61
11861963 2002
7
Angiotensin-converting enzyme gene I/D polymorphism in malignant hypertension. 54 61
10855732 2000
8
Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. 54 61
10221353 1999
9
The importance of the renin-angiotensin system in cardiovascular disease. 54 61
9655650 1998
10
The Tsukuba hypertensive mouse (transgenic mouse carrying human genes for both renin and angiotensinogen) as a model of human malignant hypertension: development of lesions and morphometric analysis. 54 61
9504863 1998
11
Nephrosclerosis and hypertension. 54 61
9356598 1997
12
Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration. 54 61
9372330 1997
13
Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. 54 61
10968202 1996
14
Hyperrenin-hyperaldosterone-dependent malignant hypertension in polyarteritis nodosa. 54 61
7903825 1993
15
Blood pressure, angiotensin-converting enzyme (ACE) inhibitors, and the kidney. 54 61
1580276 1992
16
Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. 54 61
1908620 1991
17
Unravelling the role of interleukin-11 in renal and cardiac fibrosis in malignant hypertension. 61
32030403 2020
18
Phaeochromocytoma of the urinary bladder presenting with malignant hypertension and hypertensive retinopathy. 61
31970077 2020
19
Malignant hypertension: does this still exist? 61
31636349 2020
20
CONN SYNDROME PRESENTING AS CENTRAL RETINAL VEIN OCCLUSION. 61
28644176 2020
21
[Malignant hypertension: A bright future]. 61
31471092 2019
22
Complement Activation and Thrombotic Microangiopathies. 61
31694864 2019
23
Correlations between Interleukin-11 expression and hypertensive kidney injury in a rat model of renovascular hypertension. 61
31840157 2019
24
Comment on: "Serous retinal detachment in preeclampsia and malignant hypertension". 61
31278383 2019
25
Serous retinal detachment in preeclampsia and malignant hypertension. 61
31089238 2019
26
Elevated Plasma Renin Activity Caused by Accelerated-malignant Hypertension in a Patient with Aldosterone-producing Adenoma Complicated with Renal Insufficiency. 61
31292373 2019
27
[Cerebral amyloid angiopathy revealed or hypertension-related cerebral small vessel diseases: A clinical challenge]. 61
31466725 2019
28
Demyelinating syndrome in systemic sclerosis and neuromyelitis optica. 61
31607267 2019
29
Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. 61
31420192 2019
30
Takayasu arteritis: differential diagnosis in a teenager with severe acute kidney injury - a case report. 61
30638252 2019
31
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. 61
31733722 2019
32
Hyperhomocysteinemia: a trigger for complement-mediated TMA? 61
31401947 2019
33
Atypical Presentation of Renal Leiomyosarcoma: A Case Report. 61
31632881 2019
34
Posterior reversible encephalopathy syndrome in stroke-prone spontaneously hypertensive rats on high-salt diet. 61
29350576 2019
35
Patterns of renal disease: A 30-year renal biopsy study at Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, South Africa. 61
31266574 2019
36
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis. 61
30809002 2019
37
Systemic Sclerosis with Focus on Scleroderma Renal Crisis. 61
31209194 2019
38
Takayasu arteritis, malignant hypertension and severe left ventricular hypertrophy. 61
30861323 2019
39
Factors associated with adverse outcomes from cardiovascular events in the kidney transplant population: an analysis of national discharge data, hospital characteristics, and process measures. 61
31138156 2019
40
Hypertensive Choroidopathy Revealing Malignant Hypertension in a Young Patient. 61
30893276 2019
41
Fundoscopy and malignant hypertension. 61
30395318 2019
42
Etiology and Outcomes of Thrombotic Microangiopathies. 61
30862697 2019
43
The exaggerated salt-sensitive response in hypertensive transgenic rats (TGR mRen-2) fostered by a normotensive female. 61
30531845 2019
44
The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management. 61
30871486 2019
45
Malignant hypertension: not quite an obsolete diagnosis yet. 61
30640869 2019
46
Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. 61
30160657 2019
47
Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. 61
30891033 2019
48
A Case of Rheumatoid Arthritis Presenting with Renal Thrombotic Microangiopathy Probably due to a Combination of Chronic Tacrolimus Arteriolopathy and Severe Hypertension. 61
30963011 2019
49
Macular edema secondary to malignant Hypertension managed with Intravitreal Bevacizumab. 61
31523075 2019
50
Conditions and Factors Associated With Spontaneous Coronary Artery Dissection (from a National Population-Based Cohort Study). 61
30477805 2019

Variations for Malignant Hypertension

Expression for Malignant Hypertension

Search GEO for disease gene expression data for Malignant Hypertension.

Pathways for Malignant Hypertension

GO Terms for Malignant Hypertension

Cellular components related to Malignant Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.8 TRPC6 TRPC3 EDN1 AGTR1 AGT ADM
2 extracellular space GO:0005615 9.7 THBD REN NPPB NPPA EDN1 CHGA
3 extracellular region GO:0005576 9.4 VWF REN NPPB NPPA EDN1 CHGA
4 cation channel complex GO:0034703 9.26 TRPC6 TRPC3
5 Weibel-Palade body GO:0033093 9.16 VWF EDN1

Biological processes related to Malignant Hypertension according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.88 TRPC6 CYP1A1 AGT ADM
2 negative regulation of cell growth GO:0030308 9.87 NPPB NPPA AGT
3 response to hypoxia GO:0001666 9.87 NPPA EDN1 CYP1A1 ADM
4 response to organic substance GO:0010033 9.83 REN CYP1A1 ADM
5 kidney development GO:0001822 9.83 REN AGTR1 AGT ACE
6 platelet activation GO:0030168 9.8 VWF TRPC6 TRPC3 ADAMTS13
7 response to wounding GO:0009611 9.79 VWF CYP1A1 ADM
8 response to lipopolysaccharide GO:0032496 9.77 THBD REN EDN1 CYP1A1 ADM
9 hemostasis GO:0007599 9.76 VWF THBD ADAMTS13
10 female pregnancy GO:0007565 9.76 THBD NPPA AGT ADM
11 positive regulation of cytosolic calcium ion concentration GO:0007204 9.72 TRPC6 EDN1 AGTR1 AGT ADM
12 regulation of the force of heart contraction GO:0002026 9.69 CHGA ADM
13 vasoconstriction GO:0042310 9.69 EDN1 AGT
14 positive regulation of cellular protein metabolic process GO:0032270 9.68 AGTR1 AGT
15 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.68 AGTR1 AGT
16 cell growth involved in cardiac muscle cell development GO:0061049 9.68 NPPA AGT
17 peptide catabolic process GO:0043171 9.68 ADAMTS13 ACE
18 response to muscle stretch GO:0035994 9.67 NPPA EDN1
19 amyloid-beta metabolic process GO:0050435 9.67 REN ACE
20 negative regulation of blood coagulation GO:0030195 9.67 THBD EDN1
21 positive regulation of urine volume GO:0035810 9.66 NPPB EDN1
22 low-density lipoprotein particle remodeling GO:0034374 9.66 AGTR1 AGT
23 negative regulation of systemic arterial blood pressure GO:0003085 9.65 NPPB NPPA
24 angiotensin maturation GO:0002003 9.65 REN ACE
25 positive regulation of heart rate GO:0010460 9.65 NPPA EDN1 ADM
26 positive regulation of cardiac muscle contraction GO:0060452 9.64 NPPA CHGA
27 cGMP biosynthetic process GO:0006182 9.64 NPPB NPPA
28 artery smooth muscle contraction GO:0014824 9.63 EDN1 AGT
29 receptor guanylyl cyclase signaling pathway GO:0007168 9.63 NPPB NPPA
30 manganese ion transport GO:0006828 9.62 TRPC6 TRPC3
31 positive regulation of cholesterol esterification GO:0010873 9.61 AGTR1 AGT
32 body fluid secretion GO:0007589 9.61 NPPB EDN1
33 regulation of blood vessel diameter GO:0097746 9.61 NPPB AGTR1 ACE
34 maternal process involved in parturition GO:0060137 9.6 EDN1 CYP1A1
35 positive regulation of NAD(P)H oxidase activity GO:0033864 9.59 AGTR1 AGT
36 positive regulation of renal sodium excretion GO:0035815 9.58 NPPB EDN1 AGT
37 regulation of renal sodium excretion GO:0035813 9.56 AGTR1 AGT
38 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.55 AGTR1 AGT
39 regulation of blood volume by renin-angiotensin GO:0002016 9.54 REN AGT
40 regulation of renal output by angiotensin GO:0002019 9.51 AGT ACE
41 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGTR1 AGT ACE
42 renin-angiotensin regulation of aldosterone production GO:0002018 9.33 REN AGTR1 AGT
43 regulation of vasoconstriction GO:0019229 9.26 EDN1 AGTR1 AGT ACE
44 regulation of blood pressure GO:0008217 9.17 REN NPPB NPPA EDN1 CHGA AGT

Molecular functions related to Malignant Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 REN NPPB NPPA EDN1 ADM
2 inositol 1,4,5 trisphosphate binding GO:0070679 9.37 TRPC6 TRPC3
3 store-operated calcium channel activity GO:0015279 9.32 TRPC6 TRPC3
4 hormone receptor binding GO:0051427 9.26 NPPB NPPA
5 hormone activity GO:0005179 9.02 NPPB NPPA EDN1 AGT ADM
6 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE

Sources for Malignant Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....